SHANGHAI – Inventisbio Inc., of Shanghai, has emerged from stealth, nabbing $19 million in series B financing from health care venture financiers Orbimed and Lilly Asia Ventures (LAV). Founded in 2015, Inventisbio has a pipeline of four small-molecule preclinical drug candidates for cancer and gout.